10 research outputs found
Polyantigenic Interferon-γ Responses Are Associated with Protection from TB among HIV-Infected Adults with Childhood BCG Immunization
Surrogate immunologic markers for natural and vaccine-mediated protection against tuberculosis (TB) have not been identified. HIV-infected adults with childhood BCG immunization entering the placebo arm of the DarDar TB vaccine trial in Dar es Salaam, Tanzania, were assessed for interferon gamma (IFN-γ) responses to three mycobacterial antigen preparations--secreted Mycobacterium tuberculosis antigens 85 (Ag85), early secretory antigenic target 6 (ESAT-6) and polyantigenic whole cell lysate (WCL). We investigated the association between the number of detectable IFN-γ responses at baseline and the subsequent risk of HIV-associated TB. During a median follow-up of 3.3 years, 92 (9.4%) of 979 placebo recipients developed TB. The incidence of TB was 14% in subjects with no detectable baseline IFN-γ responses vs. 8% in subjects with response to polyantigenic WCL (P = 0.028). Concomitant responses to secreted antigens were associated with further reduction in the incidence of HIV-associated TB. Overall the percentage of subjects with 0, 1, 2 and 3 baseline IFN-γ responses to mycobacterial preparations who developed HIV-associated TB was 14%, 8%, 7% and 4%, respectively (P = 0.004). In a multivariate Cox regression model, the hazard of developing HIV-associated TB was 46% lower with each increment in the number of detectable baseline IFN-γ responses (P<0.001). Among HIV-infected adults who received BCG in childhood and live in a TB-endemic country, polyantigenic IFN-γ responses are associated with decreased risk of subsequent HIV-associated TB. ClinicalTrials.gov NCT0052195
Omics-based molecular techniques in oral pathology centred cancer: Prospect and challenges in Africa
: The completion of the human genome project and the accomplished milestones in the human
proteome project; as well as the progress made so far in computational bioinformatics and “big data” processing have
contributed immensely to individualized/personalized medicine in the developed world.At the dawn of precision medicine, various omics-based therapies and bioengineering can now be
applied accurately for the diagnosis, prognosis, treatment, and risk stratifcation of cancer in a manner that was
hitherto not thought possible. The widespread introduction of genomics and other omics-based approaches into
the postgraduate training curriculum of diverse medical and dental specialties, including pathology has improved
the profciency of practitioners in the use of novel molecular signatures in patient management. In addition, intricate
details about disease disparity among diferent human populations are beginning to emerge. This would facilitate the
use of tailor-made novel theranostic methods based on emerging molecular evidences
Recommended from our members
HD 202772A b: A Transiting Hot Jupiter around a Bright, Mildly Evolved Star in a Visual Binary Discovered by TESS
We report the first confirmation of a hot Jupiter discovered by the Transiting Exoplanet Survey Satellite (TESS) mission: HD 202772A b. The transit signal was detected in the data from TESS Sector 1, and was confirmed to be of planetary origin through radial velocity (RV) measurements. HD 202772A b is orbiting a mildly evolved star with a period of 3.3 days. With an apparent magnitude of V = 8.3, the star is among the brightest and most massive known to host a hot Jupiter. Based on the 27 days of TESS photometry and RV data from the CHIRON, HARPS, and Tillinghast Reflector Echelle Spectrograph, the planet has a mass of and radius of , making it an inflated gas giant. HD 202772A b is a rare example of a transiting hot Jupiter around a quickly evolving star. It is also one of the most strongly irradiated hot Jupiters currently known
Vulnerable newborn types: analysis of subnational, population‐based birth cohorts for 541 285 live births in 23 countries, 2000–2021
Objective: To examine prevalence of novel newborn types among 541 285 live births in 23 countries from 2000 to 2021. Design: Descriptive multi-country secondary data analysis. Setting: Subnational, population-based birth cohort studies (n = 45) in 23 low- and middle-income countries (LMICs) spanning 2000–2021. Population: Liveborn infants. Methods: Subnational, population-based studies with high-quality birth outcome data from LMICs were invited to join the Vulnerable Newborn Measurement Collaboration. We defined distinct newborn types using gestational age (preterm [PT], term [T]), birthweight for gestational age using INTERGROWTH-21st standards (small for gestational age [SGA], appropriate for gestational age [AGA] or large for gestational age [LGA]), and birthweight (low birthweight, LBW [<2500 g], nonLBW) as ten types (using all three outcomes), six types (by excluding the birthweight categorisation), and four types (by collapsing the AGA and LGA categories). We defined small types as those with at least one classification of LBW, PT or SGA. We presented study characteristics, participant characteristics, data missingness, and prevalence of newborn types by region and study. Results: Among 541 285 live births, 476 939 (88.1%) had non-missing and plausible values for gestational age, birthweight and sex required to construct the newborn types. The median prevalences of ten types across studies were T+AGA+nonLBW (58.0%), T+LGA+nonLBW (3.3%), T+AGA+LBW (0.5%), T+SGA+nonLBW (14.2%), T+SGA+LBW (7.1%), PT+LGA+nonLBW (1.6%), PT+LGA+LBW (0.2%), PT+AGA+nonLBW (3.7%), PT+AGA+LBW (3.6%) and PT+SGA+LBW (1.0%). The median prevalence of small types (six types, 37.6%) varied across studies and within regions and was higher in Southern Asia (52.4%) than in Sub-Saharan Africa (34.9%). Conclusions: Further investigation is needed to describe the mortality risks associated with newborn types and understand the implications of this framework for local targeting of interventions to prevent adverse pregnancy outcomes in LMICs